Trastuzumab Not Yet Recruiting Phase 2 Trials for HER-2 protein overexpression / Cholangiocarcinomas / HER-2 Gene Amplification / Biliary Tract Cancer Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03613168Trastuzumab in HER2-positive Biliary Tract Cancer